{"entity":{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","aka":[],"tldr":"Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer.","summary":"Shannon Westin is a gynaecologic oncologist and clinical trialist at MD Anderson Cancer Center. She was first author of the 2023 Journal of Clinical Oncology report of DUO-E, the phase 3 trial in which durvalumab with carboplatin and paclitaxel, followed by durvalumab with or without olaparib maintenance, improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer, with the largest benefit in mismatch repair-deficient tumours.","asOf":"2026-09-18","links":[],"tags":["endometrial","gynaecological","trialist"],"related":[],"cancers":["advanced-recurrent-endometrial-cancer","endometrial","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-duo-e-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Endometrial cancer","Ovarian cancer","Targeted and immune therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%5BAuthor%5D"}],"papers":[],"orcid":"0000-0002-1922-0156"},"route":"/people/shannon-westin/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"paper":[{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","route":"/key-papers/paper-duo-e-jco-2023/"}]}}